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Background: We investigated a large population of patients with chronic obstructive pul-
monary disease (COPD) to determine their frequency of medication use and patterns of 
pharmacotherapy.
Methods: Medical and pharmacy claims data were retrospectively analyzed from 19 health plans 
(.7.79 million members) across the US. Eligible patients were aged $40 years, continuously 
enrolled during July 2004 to June 2005, and had at least one inpatient or at least two outpatient 
claims coded for COPD. As a surrogate for severity of illness, COPD patients were stratified 
by complexity of illness using predefined International Classification of Diseases, Ninth Revi-
sion, Clinical Modification, Current Procedural Terminology, Fourth Edition, and Healthcare 
Common Procedure Coding System codes.
Results: A total of 42,565 patients with commercial insurance and 8507 Medicare patients were 
identified. Their mean age was 54.7 years and 74.8 years, and 48.7% and 46.9% were male, 
respectively. In total, 66.3% of commercial patients (n = 28,206) were not prescribed any main-
tenance COPD pharmacotherapy (59.1% no medication; 7.2% inhaled short-acting β2-agonist 
only). In the Medicare population, 70.9% (n = 6031) were not prescribed any maintenance 
COPD pharmacotherapy (66.0% no medication; 4.9% short-acting β2-agonist only). A subset 
of patients classified as high-complexity were similarly undertreated, with 58.7% (5358/9121) 
of commercial and 68.8% (1616/2350) of Medicare patients not prescribed maintenance COPD 
pharmacotherapy. Only 18.0% and 9.8% of diagnosed smokers in the commercial and Medicare 
cohorts had a claim for a smoking cessation intervention and just 16.6% and 23.5%, respectively, 
had claims for an influenza vaccination.
Conclusion: This study highlights a high degree of undertreatment of COPD in both com-
mercial and Medicare patients, with most patients receiving no maintenance pharmacotherapy 
or influenza vaccination.
Keywords: managed care, chronic obstructive pulmonary disease, health care utilization, 
quality of care
Introduction
The World Health Organization estimates chronic obstructive pulmonary disease 
(COPD) to be the fourth leading cause of death, accounting for at least 5% of all 
deaths worldwide (about 3.02 million).1 This is likely an underestimate of COPD 
mortality, given that COPD patients often have a high number of comorbidities and 
complications,2,3 and airflow obstruction is an important contributor to other causes 
of morbidity and mortality.4,5
Advances in pharmacotherapy and improvements in COPD disease management 
have brought about the realization that COPD is a preventable and treatable disease.2 International Journal of COPD 2012:7 submit your manuscript | www.dovepress.com
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These advances have also resulted in the development of 
COPD diagnosis and treatment guidelines,6–9 which are 
widely available to health care practitioners. Treatment 
guidelines aim to increase awareness of COPD and improve 
patient management and outcomes. For example, the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
guidelines recommend that an effective COPD management 
plan should include assessment and monitoring of the disease, 
reduction in risk factors, management of stable COPD, and 
management of exacerbations.9,10
Despite the widespread availability of evidence-based 
guidelines, survey results suggest that practitioners have 
major gaps in their knowledge of the core elements of 
COPD management, with at least 50% reportedly unaware 
of guidelines for COPD diagnosis and treatment.11 This lack 
of knowledge of recommended treatment may lead to sub-
optimal management of COPD patients in the primary care 
setting. COPD is a progressive illness with worsening symp-
toms, and therefore patients need to be actively prescribed 
appropriate therapies and to have ongoing assessments to 
manage their COPD and improve their health status.
In this retrospective analysis of managed care patients, 
we sought to document and evaluate patterns of medication 
utilization and medication-related assessments recorded for 
COPD patients. Medication utilization, adherence, and indi-
cators of treatment and care were analyzed to assess treatment 
of COPD patients based on recognized   guidelines. A sub-
group of COPD patients with the most severe or complex 
COPD were identified and analyzed to determine if COPD 
severity changes the patterns of medication use in this cohort 
of commercial and Medicare patients.
Materials and methods
study design
Continuously eligible populations from commercial, 
Medicare, and Medicaid membership of large, national US 
health plans including 12.4 million covered lives were identi-
fied from the PharMetrics database (Watertown, MA). The 
database included 19 health plans across the US: 3.2   million 
from the Northeast, 6.4 million from the Midwest, 1.8   million 
from the South, and 0.7 million from the West. The plans 
varied in size: six were ,200,000 covered lives, nine 
were between 200,001 and one million covered lives, and 
four were over one million covered lives.12 Pharmacy and 
medical claims from the 7.79 million members who were 
continuously eligible during the study period (July 2004 
and June 2005) were retrospectively analyzed for COPD 
cohorts. Medicaid (a government-funded program   primarily 
for indigent younger adults and children) claims data were 
analyzed, but are not reported here because only 485 of 
83,007 patients were identified as having COPD. Patient 
stratification is outlined in Figure 1. The commercial popu-
lation represented employees and their eligible dependants 
from employer-based health insurance product offerings, 
including health maintenance organization, preferred pro-
vider organization, and point of service plans. Medicare is 
a government-sponsored health care program for patients 
aged $65 years and for others with certain disabilities. The 
Medicare population in this analysis includes persons who 
chose to have this benefit managed by a private insurance 
company. Additional details of the populations studied in 
this analysis have been reported elsewhere.12
Identification of populations
Patients were identified as having COPD if they were 
aged $40 years and had any one of the following:
•	 One inpatient hospitalization or one emergency room 
encounter with a COPD diagnosis (2004 International 
Classification of Diseases, Ninth Revision, Clinical Modi-
fication [ICD-9-CM] codes 491.x [chronic bronchitis], 
492.x [emphysema], or 496 [chronic airway obstruction]) 
listed in any position as a discharge diagnosis
•	 Two professional claims, with different dates of services, 
with a COPD diagnosis listed in any position
•	 A COPD-related surgical procedure (eg, lung volume 
reduction) listed on either a professional or facility claim. 
COPD-related surgical procedures included open   excision 
Patients in overall dataset
N = 7,869,677
Patients in Medicare
subgroup
N = 115,652
Patients identified
with COPD
N = 8507
Filter for high-
complexity criteria*
High-
complexity
patients
N = 2350 (27.6%)
High-
complexity
patients
N = 9121 (21.4%)
Patients identified
with COPD
N = 42,565
Patients in commercial
subgroup
N = 7,671,018
Filter for high-
complexity criteria*
Criteria
met
Criteria
met
Figure 1 Flow of patients through the study. Complexity is used as a surrogate 
for COPD disease severity, and methodology for classification is described in full 
elsewhere.12
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plication of bullae of lung, open excision plication of 
emphysematous lung(s) for lung volume reduction, and 
thoracoscopy with excision plication of bullae of lung.
Medication utilization
Use of COPD medication(s) was analyzed during the 
one-year period based on pharmacy claims in the datasets. 
A patient was considered to be taking a medication if they 
had at least one filled prescription for that medication product 
during the one-year study period. The following medications 
were considered maintenance COPD pharmacotherapy: 
long-acting β2-agonist bronchodilators (LABA), short-
acting or long-acting anticholinergic bronchodilators (SAAC 
and LAAC, respectively), methylxanthine bronchodilators 
(theophylline), and inhaled corticosteroids. As per the GOLD 
guidelines, short-acting β2-agonists (SABAs) were consid-
ered symptomatic medications or rescue drugs.10 Medication 
utilization is reported in two ways:
•	 Medications of interest, which represent the number of 
COPD patients who filled at least one prescription for a 
defined medication class (or fixed-dose combination) of a 
respiratory or nonrespiratory medication (eg, antimicrobi-
als, narcotic analgesics, diuretics, antidepressants, anxi-
olytics/sedatives, gastrointestinal antisecretory/antiulcer 
agents, β-blockers, antihistamines [not part of cough/cold 
preparations], smoking deterrents/nicotine replacements, 
gastrointestinal promotility agents, antiarrhythmia agents) 
during the one-year study period. Reporting in this manner 
is not mutually exclusive and patients could be receiving 
more than one medication of interest.
•	 Medication patterns, which represent the number of 
COPD patients who filled at least one prescription for 
each defined respiratory drug class or drug class com-
bination during the one-year study period. Reporting 
in this manner is mutually exclusive and patients could 
only be classified as receiving one medication pattern. 
Medication patterns are used to evaluate the proportion 
of patients who received single or multiple maintenance 
COPD medications and for identifying patients receiving 
single or multiple therapies during the one-year study 
period as well as those receiving no therapy or SABA 
therapy alone.
To illustrate the differences between these two methods of 
reporting, a patient who received an inhaled anticholinergic 
and an inhaled corticosteroid during the study period was 
reported in both classes in medications of interest, but only 
in the anticholinergic + inhaled corticosteroid category of 
medication patterns.
In order to characterize further medication use in this 
population of COPD patients, the following were also 
assessed: claims for smoking cessation therapy in COPD 
patients documented to be current smokers (based on current 
tobacco use using ICD-9-CM codes); use of a maintenance 
COPD pharmacotherapy within 45 days following a hos-
pitalization for a COPD exacerbation;13 and proportion of 
patients vaccinated against influenza.
high-complexity criteria for medication 
pattern reporting
The guidelines are clear that patients with more severe disease 
should receive maintenance COPD pharmacotherapy.10 We 
therefore conducted an analysis of a subset with likely more 
severe disease. Claims data do not contain pulmonary function 
test values, and it was therefore not possible to assess COPD 
severity according to the GOLD guidelines.10 Instead, a claims-
based classification of COPD complexity was used to serve as a 
surrogate for COPD disease severity. The methodology for this 
has been described fully elsewhere.12 For this analysis,   comorbid 
respiratory conditions and medical procedures occurring during 
the study period were used to assign patients to a high complexity 
subset, based on selected diagnostic,   therapeutic, procedures, 
and services codes (2004 ICD-9-CM, Current Procedural 
Te  rminology, Fourth Edition, and Healthcare Common Proce-
dure Coding System).12 For example, a patient with a claim 
for t  uberculosis, malignant neoplasm, or cor pulmonale was 
classified as high complexity. A medications patterns analysis 
is reported for this high-complexity subset.
Adherence
Adherence to prescribed medications was estimated using 
pharmacy claims by calculating a medication possession 
ratio (MPR), defined as the total days of medication supplied 
in all prescription fills/total days between the first and last 
fill + days supplied in last prescription. MPR is a commonly 
used metric to assess adherence/compliance.14 Adherence 
with noninhaled medications (tablets, capsules, liquids) was 
calculated using the actual reported days of supply from the 
claims data. However, because the days of supply reported 
in pharmacy claims for inhaled medication prescriptions is 
often unreliable, the number of “days supplied” for inhaled 
medications was assigned a value based on average adult 
doses (in number of puffs) for each product and the number 
of puffs per container. Adherence to each respiratory medica-
tion is reported as the average MPR for all patients receiving 
two or more prescriptions of a relevant medication. MPR was 
only calculated for maintenance COPD medications.International Journal of COPD 2012:7 submit your manuscript | www.dovepress.com
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Data collection and outcome measures
DTEC™ software (Version 3.3, Pfizer, New York, NY) 
was used to integrate administrative data and claims files, 
identify and stratify patients with COPD, as well as to 
characterize demographics, comorbidities (respiratory and 
nonrespiratory), and utilization of medications. All analyses 
were specified prior to the study and programmed in the 
software.12 These analyses, including rationale for complexity 
stratification, were developed by a panel of experts including 
pulmonologists, outcomes researchers, and claims-based 
research consultants.12 They were developed based on infor-
mation from accepted guidelines,9,15 but also incorporate the 
previous experiences of the panel in claims-based research. 
While DTEC (a proprietary software program) was used for 
these analyses, the algorithms for the data reported have been 
specifically outlined and published previously,12 in order that 
they may be used in other claims querying systems.
Claims data during the 1-year study period were ana-
lyzed and are presented as means with standard deviations. 
Categorical data are presented as numbers and percentages. 
The database was compiled in accordance with all aspects 
of the Health Information Portability and Accountability 
Act of 1996.
Results
Identification of COPD population
Of the 7,869,677 patients in the overall dataset, 42,565 
commercial and 8507 Medicare patients were identified as 
having COPD (Figure 1). Among these two groups, 21.4% of 
commercial (9121/42,565) and 27.6% of Medicare patients 
(2350/8507) were categorized as high-complexity, based 
on comorbid respiratory and nonrespiratory conditions and 
claims for procedures and services.12
Population characteristics
Patients with COPD from the commercial and Medicare data 
sets had a mean age of 54.7 years and 74.8 years, respectively, 
and approximately half were male (Table 1). The most com-
mon comorbidity was hypertension in both data sets (55.2% 
commercial; 71.6% Medicare) followed by dyslipidemia 
(48.2% commercial; 47.3% Medicare). The majority of 
patients recorded at least one office visit/consultation (98.7% 
commercial; 96.4% Medicare) with a mean of 11.3 visits in 
the commercial group and 11.5 visits in the Medicare group 
during the one-year study period. More than half (53.9%) of 
the Medicare cohort and nearly 40% of the commercial cohort 
(39.8%) were hospitalized at least once for any reason during 
the study period. In total, 1651 Medicare patients (19.4%) and 
5922 commercial patients (13.9%) were hospitalized at least 
once due to COPD. Additional details describing these COPD 
populations have been published in full elsewhere.12
Medication utilization
Medications of interest
The proportion of COPD patients in the commercial and 
Medicare populations receiving different classes of respiratory 
and nonrespiratory drugs are shown in Table 2. Oral corticos-
teroids and SABAs were the most commonly filled respiratory 
medications in commercial (30.1%; 30.0%) and Medicare 
(20.9%; 25.5%) populations, respectively. Systemic antibiotics 
or antimicrobials were the most common non-COPD medica-
tions used in both data sets, prescribed to 57.7% and 40.2% of 
the commercial and Medicare populations, respectively.
Medication patterns
Figure 2 shows patterns of medication use, and indicates that 
the majority of patients in both cohorts did not receive any 
Table 1 Patient characteristics
Commercial Medicare
All 
(n = 42,565)
High complexity 
(n = 9121; 21.4%)
All 
(n = 8507)
High complexity 
(n = 2350; 27.6%)
Age, years
  Mean ± sD 
Age, n (%) 
  40–44 years 
  45–54 years 
  55–64 years 
  65–74 years 
  75–84 years 
  $85 years
54.7 ± 6.1 
 
2960 (7.0) 
14,432 (33.9) 
25,173 (59.1) 
0 (0) 
0 (0) 
0 (0)
55.1 ± 6.0 
 
572 (6.3) 
2911 (31.9) 
5638 (61.8) 
0 (0) 
0 (0) 
0 (0)
74.8 ± 7.3 
 
15 (0.2) 
125 (1.5) 
460 (5.4) 
3367 (39.6) 
3625 (42.6) 
915 (10.8)
74.6 ± 7.6 
 
3 (0.1) 
44 (1.9) 
155 (6.6) 
896 (38.1) 
1005 (42.8) 
247 (10.5)
gender, % male 48.7 49.3% 46.9 48.8%
Abbreviation: sD, standard deviation.International Journal of COPD 2012:7 submit your manuscript | www.dovepress.com
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maintenance COPD pharmacotherapy. Figure 2A shows that 
66.3% of commercial patients (n = 28,206) received no main-
tenance COPD pharmacotherapy, including 25,157/42,565 
(59.1%) prescribed no COPD medications and 3049/42,565 
(7.2%) prescribed only inhaled SABAs. Figure 2B shows 
that 70.9% of Medicare patients (n = 6376) received no 
maintenance COPD pharmacotherapy, including 5615/8507 
(66.0%) prescribed no COPD medications, and 416/8507 
(4.9%) prescribed SABA only.
high-complexity criteria for medication pattern 
reporting
In order to evaluate medication utilization in patients with 
a high number of comorbidities who were more likely to be 
severe and compromised, we performed a similar evaluation 
for COPD patients who met criteria for high complexity (as 
a surrogate for COPD severity)12 and found similar trends. 
More than half of all high-complexity patients were not 
prescribed maintenance COPD pharmacotherapy. For the 
commercial population, 5358 (58.7%) of high-complexity 
patients did not receive any maintenance COPD pharma-
cotherapy, including 4756 (52.1%) receiving no COPD 
medications and 602 (6.6%) receiving SABAs only. Similarly, 
68.8% (1616/2350) high-complexity Medicare patients did 
not receive any maintenance COPD pharmacotherapy, includ-
ing 1504/2350 (64.0%) receiving no COPD medication and 
112/2350 (4.8%) receiving SABAs only.
Treatment measures
The evaluation of other measures of treatment also highlighted 
that COPD in both cohorts was often managed suboptimally. 
For example, smoking deterrents/nicotine replacement prod-
ucts were prescribed to less than 10% of patients in either 
population (commercial 9.4% [3990/42,565] versus Medicare 
2.8% [234/8507]). Indeed, of the commercial and Medicare 
patients diagnosed as smokers, only 18.0% (n = 1466/8104) 
and 9.8% (n = 62/636), respectively, had a claim for a 
smoking cessation intervention (medication or behavioral 
therapy) during the one-year study period. Among patients 
hospitalized for COPD, less than half of the commercial 
cohort (40.2% [1912/4757] were prescribed bronchodilator 
therapy within 45 days following their hospitalization, and 
fewer still (29.9% [359/1200]) of the older Medicare cohort. 
Furthermore, despite guidelines recommending vaccination 
against influenza as a risk reduction strategy for all patients 
with COPD, only 7070 patients (16.6%) in the commercial 
cohort and 1996 patients (23.5%) in the Medicare cohort 
were documented to have received the vaccine.
Table 2 Medications of interest: COPD patients
Medication group Commercial (n = 42,565) Medicare (n = 8507)
respiratory medications, n (%)
  Oral corticosteroids 12,810 (30.1) 1780 (20.9)
  sABA 12,782 (30.0) 2167 (25.5)
  ICS/β2-agonist combinations 9623 (22.6) 1239 (14.6)
  Ach/β2-agonist bronchodilator combinations 7762 (18.2) 1200 (14.1)
  Antitussives and expectorants 5136 (12.1) 508 (6.0)
  LAAC 4917 (11.6) 625 (7.3)
  Leukotriene modifiers 4463 (10.5) 364 (4.3)
  ICs 3071 (7.2) 665 (7.8)
  sAAC 2730 (6.4) 1024 (12.0)
  Theophylline 1746 (4.1) 266 (3.1)
  LABA 1052 (2.5) 174 (2.0)
nonrespiratory medications, n (%)
  Systemic antibiotics/antimicrobials 24,556 (57.7) 3424 (40.2)
  narcotic analgesics 15,535 (36.5) 2085 (24.5)
  Diuretics (all) 11,567 (27.2) 2490 (29.3)
  Antidepressants 11,929 (28.0) 1245 (14.6)
  Anxiolytics/sedatives 10,018 (23.5) 1547 (18.2)
  GI antisecretory/antiulcer agents 11,080 (26.0) 1712 (20.1)
	β -blocking agents 8069 (19.0) 1768 (20.8)
  Antihistamines (not part of cough/cold preparations) 5098 (12.0) 542 (6.4)
  Smoking deterrents/nicotine replacements 3990 (9.4) 234 (2.8)
  gI promotility agents 1175 (2.8) 150 (1.8)
  Antiarrhythmia agents 604 (1.4) 209 (2.5)
Abbreviations: Ach, anticholinergics; COPD, chronic obstructive pulmonary disease; gI, gastrointestinal; ICs, inhaled corticosteroids; LAAC, long-acting anticholinergics; 
LABA, long-acting β2-agonist inhaled bronchodilator; sAAC, short-acting anticholinergic; sABA, short-acting β2-agonist bronchodilator.International Journal of COPD 2012:7 submit your manuscript | www.dovepress.com
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Adherence
Medication adherence (reported as mean MPR by drug 
class) is provided in Table 3. While adherence was 
above 50% for each respiratory medication class for both 
cohorts, acceptable adherence (MPR $ 80%)14 was only 
achieved for the oral drug classes (leukotriene modifiers 
and   theophylline). Among the inhaled agents, LAAC and 
LABA had the highest average adherence, while SAAC 
had the lowest.
Discussion
This analysis of more than 51,000 patients highlights 
  significant undertreatment of COPD in typical US   commercial 
and Medicare populations. The majority of diagnosed COPD 
patients remain undertreated with no maintenance COPD 
pharmacotherapy for their COPD over the one-year study 
period.
Inhaled bronchodilators are the accepted first-line 
  therapies for symptomatic COPD management, because 
Figure 2 respiratory medication patterns in COPD patientsa. (A) Commercial (n = 42,565) and (B) Medicare (n = 8507).
Notes: aIndividual medication groups are mutually exclusive. “Other combinations” includes: theophylline (methylxanthine bronchodilator) alone; short-acting anticholinergic 
plus theophylline; anticholinergic (short-acting or long-acting) plus theophylline plus inhaled corticosteroid; LABA; long-acting anticholinergic plus inhaled corticosteroid; 
sAAC; short-acting anticholinergic plus LABA; LABA plus theophylline plus inhaled corticosteroid.
Abbreviations: Ach, anticholinergics; ICs, inhaled corticosteroid; LAAC, long-acting anticholinergic; LABA, long-acting β2-agonist inhaled bronchodilator; sAAC, short-
acting anticholinergic; sABA, short-acting β2-agonist bronchodilator.
Other combinationsa;
5.0%
Ach + LABA + ICS;
12.5%
LABA + ICS; 8.7%
SAAC + ICS; 1.7%
SAAC; 7.4%
SABA alone; 7.2%
No medication or
treatment; 59.1%
66.3%
no long-term
pharmacotherapy
A
LAAC; 2.3%
ICS; 1.6%
Other combinationsa;
4.0%
Ach + LABA + ICS;
9.7%
LABA + ICS; 4.2%
SAAC + ICS; 2.9%
SAAC; 8.9%
SABA alone; 4.9%
No medication or
treatment; 66.0%
70.9%
no long-term
pharmacotherapy
B
LAAC; 1.3%
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regular use can increase exercise capacity and improve 
health status.9,16,17 However, in the present analysis, more than 
two-thirds of COPD patients in the commercial population 
and .70% of the Medicare population were not prescribed 
any long-term maintenance COPD medications. Because 
patients with mild COPD may appropriately not be pre-
scribed long-term therapy according to GOLD guidelines, 
we also evaluated subsets of patients classified as “high-
complexity,” where complexity served as a surrogate for 
disease severity and represented patients with the highest 
number of comorbid conditions and complications.12 More 
than half of high-complexity commercial and 69% of high-
complexity Medicare patients failed to receive any mainte-
nance COPD pharmacotherapies. Although clinicians may 
be less likely to prescribe chronic COPD pharmacotherapy 
to older patients receiving multiple medications who may 
have cognitive impairment or difficulty using inhalers, the 
observation that 70% of older patients, such as those repre-
sented by the Medicare cohort, and 60% of high-complexity 
Medicare patients, did not receive even one long-term COPD 
pharmacotherapy is a cause for concern.
The effectiveness of recommended treatment regimens is 
dependent on how well patients adhere with them. Adherence 
to COPD medications in the present study based on medica-
tion refills was only about 50%, which is comparable with 
other studies,18,19 but still suboptimal for patients to derive 
benefit from therapies being prescribed.
Our findings are particularly noteworthy given recom-
mended guidelines outlining a clear strategy for COPD and 
the management of associated exacerbations.7,9,10,20 In addi-
tion, recent large, multiyear studies have shown therapies 
such as LAACs and LABA/inhaled corticosteroid combi-
nations used chronically offer significant benefits to COPD 
patients, including a reduction in exacerbation frequency and 
possibly a reduction in mortality.21,22 The undermanagement 
highlighted here is in agreement with a survey of primary care 
physicians, which reported that only 35% of physicians chose 
a long-acting bronchodilator (recommended by GOLD)10 
if use of a short-acting agent had failed to manage a patient’s 
COPD symptoms.23 Furthermore, although 55% of physicians 
were aware of major COPD guidelines (GOLD or American 
Thoracic Society/European Respiratory Society guidelines), 
only 25% used them to guide decision-making.23
In addition to highlighting the suboptimal prescription of 
COPD medications, we also found suboptimal use of certain 
non-COPD maintenance pharmacotherapies. Less than 20% 
of COPD patients in this study were documented to have 
received an influenza vaccine, despite vaccination being 
recommended for all COPD patients to reduce exacerbation 
frequency.9 In addition, 82% of patients reported to be current 
smokers in the commercial dataset did not receive any smoking 
cessation intervention. Similarly, 90% of   current smokers in 
the Medicare population did not receive smoking cessation 
interventions. The majority of COPD cases can be attributed 
to tobacco smoking,2 and smoking cessation has been shown 
to be the most effective method of slowing the progression of 
COPD.9,10,24 The evidence indicates that smoking cessation 
interventions, including non-nicotine pharmacotherapy,25,26 
or nicotine replacement therapy,27 combined with counseling, 
are both effective and cost-effective.28–30
Our data should be interpreted in light of certain 
limitations. As with any retrospective database study, the 
COPD diagnosis for patients in the present study was 
established by the presence of claims coded for this diagnosis 
from health care providers, and no spirometry results are 
available to verify diagnosis or assess disease severity. We 
compensated for the latter using a surrogate, ie, COPD 
complexity, for severity using service and procedure codes 
Table 3 Adherence (shown as average medication possession ratio) to COPD-related medications in commercial and Medicare datasets
Commercial Medicare
Evaluable  
patientsa, n
Average  
adherence, %
Evaluable  
patientsa, n
Average 
adherence, %
Leukotriene modifiers 3457 82.2 289 85.2
Theophylline 1344 81.3 228 83.4
LABA 743 71.1 113 70.5
LAAC 3250 73.6 413 76.9
ICS/β2-agonist combinations 6683 64.7 860 67.2
ICs 1720 63.0 396 66.3
Ach/β2-agonist bronchodilator combination 4660 58.1 755 57.3
sAAC 1486 52.3 674 51.8
Notes: aEvaluable patients are those recorded to be taking the given medications. Each patient included in the adherence calculation filled two or more prescriptions for the 
relevant medication.
Abbreviations: Ach, anticholinergics; COPD, chronic obstructive pulmonary disease; ICs, inhaled corticosteroids; LAAC, long-acting anticholinergics; LABA, long-acting 
β2-agonist inhaled bronchodilators; sAAC, short-acting anticholinergics; sABA, short-acting β2-agonist bronchodilators.International Journal of COPD 2012:7 submit your manuscript | www.dovepress.com
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and comorbid conditions selected by a panel of experts. It is 
possible that there is under-reporting of medication utilization 
because the study was limited to a one-year period, and 
newly diagnosed patients near the end of the inclusion period 
may not have had time to begin drug therapy. However, our 
sensitivity analyses using high-complexity patients showed 
similar underuse of COPD medications in this subgroup 
as per the whole cohort. Some diagnoses and therapies are 
consistently under-reported in claims data, including smoking 
and antismoking medications, since many health care plans 
do not cover these medications. Therefore, the proportion of 
patients recorded as smokers or taking smoking cessation 
therapies in the current study may actually be an under-
representation. While this study primarily evaluates treatment 
with pharmacotherapy, other therapies are important in the 
treatment of COPD. Other health care utilization in this 
population including hospitalization and outpatient services 
such as respiratory-related equipment and supplies (including 
oxygen) and respiratory therapy services (including assisted 
ventilation) have been reported elsewhere.12 A detailed 
analysis of oxygen therapy in a US managed care population 
has also been reported previously.31
Medication adherence was estimated using reasonable 
assumptions for patients who filled more than two   prescriptions. 
Patients who filled only one prescription and could be, 
t  herefore, nonadherent, were not included in the calculation. 
Our method of estimating the number of “days   supplied” 
for inhaled drugs based upon recommended doses and 
number of puffs/inhaler,32 could be inaccurate in patients 
on unusual doses. While these assumptions are reasonable 
for the population as a whole, unusual dosing in a specific 
patient could result in inaccurate MPRs. We cannot account 
for prescriptions that were filled but not taken by the patient, 
or for medication samples that may have been dispensed by 
the health plan physicians, because these are not accounted 
for in claims data. Because the study was a cross-sectional 
analysis, no cause and effect analyses could be conducted. 
Analysis of the management of comorbid conditions was 
beyond the scope of this analysis.
Our study used data from 2004 to 2005, prior to the publi-
cation of landmark studies, such as the Towards a Revolution 
in COPD Health (TORCH) and the Understanding Potential 
Long-Term Impacts on Function with Tiotropium (UPLIFT®) 
studies,21,22 which demonstrated significant benefits of pro-
viding maintenance pharmacotherapy for COPD.33 Although 
we hope that the undertreatment documented in the present 
study has improved with the publication of these studies, the 
magnitude of our findings and their consistency with other 
reports34,35 make it very likely that a significant problem with 
the undermanagement of COPD patients still exists.
Conclusion
This study highlights marked undertreatment of COPD in 
both commercial and Medicare managed care populations. 
The majority of patients with COPD, even those with a high 
number of comorbidities, were untreated with respiratory 
medications. Adherence with COPD therapies was subop-
timal, and related therapies, such as smoking cessation and 
influenza vaccinations, were underprescribed. These findings 
suggest that there is significant opportunity to improve the 
lives of patients with COPD with appropriate treatment. 
A major educational effort is needed to disseminate evidence-
based guidelines supported by recent landmark trials to health 
care providers, and educate providers and patients on the 
long-term benefits of appropriately treating COPD.
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